| Recruiting | Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective NCT07358910 | Institut Pasteur du Cambodge | — |
| Not Yet Recruiting | Correlation of Protection Against Varicella in an Exploratory Study NCT06482216 | Sinovac (Dalian) Vaccine Technology Co., Ltd. | — |
| Completed | Simultaneous Administration Study of Varicella Attenuated Live Vaccine and Trivalent Inactivated Influenza Vac NCT06987942 | Sinovac (Dalian) Vaccine Technology Co., Ltd. | Phase 4 |
| Enrolling By Invitation | An Immunity Persistence Study of Booster Dose of Live Attenuated Varicella Vaccine NCT06484686 | Sinovac (Dalian) Vaccine Technology Co., Ltd. | Phase 4 |
| Completed | Immunogenicity and Safety of Varicella Vaccine, Live in Healthy Children Aged 12~15 Months in the Philippines NCT06314724 | Sinovac (Dalian) Vaccine Technology Co., Ltd. | Phase 3 |
| Unknown | A Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamic Profile of TNM005 in Healthy Adult Subjec NCT06068608 | Zhuhai Trinomab Pharmaceutical Co., Ltd. | Phase 1 |
| Unknown | Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine Coadministered With Two Attenuated Vaccines NCT05952505 | Shanghai Municipal Center for Disease Control and Prevention | Phase 4 |
| Unknown | A Trial to Evaluate the Lot-to-lot Consistency of Live Attenuated Varicella Vaccine in Healthy People 1-12 Yea NCT05839301 | China National Biotec Group Company Limited | Phase 3 |
| Active Not Recruiting | A Phase III Clinical Trial to Evaluate the Efficacy and Safety of the Live Attenuated Varicella Vaccine NCT05669625 | China National Biotec Group Company Limited | Phase 3 |
| Unknown | Immunogenicity, Safety and Protective Effect of Live Attenuated Varicella Vaccine and Study on Antibody Level NCT05460429 | Sinovac (Dalian) Vaccine Technology Co., Ltd. | Phase 4 |
| Unknown | Protective Effect, Safety and Immunogenicity of Live Attenuated Varicella Vaccine in Anhui Province NCT05470855 | Sinovac (Dalian) Vaccine Technology Co., Ltd. | Phase 4 |
| Recruiting | Evaluate the Safety and Immunogenicity After MG1111(BARICELA Inj.) as 2nd Vaccination in 4 ~ 6 Year Old Health NCT05422508 | Green Cross Corporation | Phase 2 |
| Completed | Safety and Immunogenicity of Live Attenuated Varicella Vaccine in Healthy Population Aged ≥13 Years Old NCT05158777 | Shanghai Institute Of Biological Products | Phase 3 |
| Enrolling By Invitation | An Immunity Persistence Study of Live Attenuated Varicella Vaccine NCT05095701 | Sinovac (Dalian) Vaccine Technology Co., Ltd. | Phase 4 |
| Enrolling By Invitation | Safety and Immunogenicity of Live Attenuated Varicella Vaccine in Healthy Population Aged ≥13 Years Old NCT05015686 | Sinovac (Dalian) Vaccine Technology Co., Ltd. | Phase 3 |
| Completed | A Study of Combined Immunization With Live Attenuated Varicella Vaccine and Inactivated Hepatitis A Vaccine NCT05526820 | Sinovac (Dalian) Vaccine Technology Co., Ltd. | Phase 4 |
| Completed | Evaluation of the Immunogenicity and Safety of VARIVAX™ in Healthy Russians (V210-058) NCT03843632 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | An Open-labelled Clinical Trial of Live Attenuated Varicella Vaccines to Evaluate the Immunity Persistence Aft NCT05150392 | Sinovac (Dalian) Vaccine Technology Co., Ltd. | Phase 3 |
| Completed | Evaluation of Immunogenicity and Safety of VARIVAX® Passage Extension 34 (PE34) Process in Children (V210-A03) NCT03239873 | Merck Sharp & Dohme LLC | Phase 3 |
| Recruiting | Pediatric and Ambulatory Research in Infectious Diseases NCT04471493 | Association Clinique Thérapeutique Infantile du val de Marne | — |
| Unknown | Safety and Immunogenicity of Measles Vaccine, Varicella Vaccine and Hepatitis-A Vaccine NCT03330171 | University of Witwatersrand, South Africa | Phase 4 |
| Completed | A Blind, Randomized and Controlled Study of Live Attenuated Varicella Vaccines NCT02981836 | Sinovac (Dalian) Vaccine Technology Co., Ltd. | Phase 3 |
| Completed | Immunogenicity and Safety of NBP608 Compared to Varivax in Healthy Children 12 Months to 12 Years of Age NCT03114943 | SK Bioscience Co., Ltd. | Phase 3 |
| Completed | The Evaluation of Immunogenicity and Safety of NBP608 in Healthy Children 12 Months to 12 Years of Age NCT03114982 | SK Chemicals Co., Ltd. | Phase 2 |
| Completed | A Safety Study of Live Attenuated Varicella Vaccines in Healthy Adults, Adolescents and Children NCT02965404 | Sinovac (Dalian) Vaccine Technology Co., Ltd. | Phase 1 |
| Withdrawn | Response and Clearance of Viral DNA Following Administration of Live Attenuated Varicella Vaccine. NCT02692066 | University of Colorado, Denver | — |
| Completed | Study of Immunogenicity, Reactogenicity and Safety of the Combined Measles, Mumps and Rubella Vaccine Produced NCT01991899 | The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) | Phase 3 |
| Withdrawn | A Study to Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX™ Manufactured With a New Process ( NCT01626794 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Immunogenicity and Safety of 2 Doses of Live Attenuated Varicella Vaccine NCT02173899 | Changchun Keygen Biological Products Co., Ltd. | Phase 4 |
| Completed | A Phase 3 Lot-consistency Clinical Trial of Live Attenuated Varicella Vaccine NCT03555071 | Sinovac (Dalian) Vaccine Technology Co., Ltd. | Phase 3 |
| Completed | Evaluation of Immunogenicity and Safety of VARIVAX™ New Seed Process (NSP) in Children (V210-063) NCT02062502 | Merck Sharp & Dohme LLC | Phase 3 |
| Withdrawn | Safety Study of Measles-Mumps-Rubella-Varicella (MMRV) Vaccine, Priorix-Tetra™ in Children Living in the Phili NCT01738841 | GlaxoSmithKline | — |
| Unknown | The Safety and Immunogenicity Research of Live Attenuated Varicella Vaccine After the 2 Doses Vaccination NCT01866566 | Beijing Center for Disease Control and Prevention | Phase 4 |
| Unknown | The Safety, Immunogenicity and Immune Effect Research of the Varicella Vaccine After the 2nd Dose Vaccination NCT01830283 | Beijing Center for Disease Control and Prevention | Phase 4 |
| Unknown | Study on Effectiveness of 2-dose Live Attenuated Varicella Vaccine NCT02146469 | Shanghai Municipal Center for Disease Control and Prevention | Phase 4 |
| Completed | Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine Made With an NCT01536405 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Immunogenicity and Safety Study of PriorixTetra™ When Co-administered With Conjugated MenC Vaccine in Healthy NCT01506193 | GlaxoSmithKline | Phase 3 |
| Completed | Study of Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Children Previously Immunized With JE-CV NCT01190228 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Comparison of GSK Measles-mumps-rubella-varicella (MMRV) Vaccine Versus PriorixTM NCT00969436 | GlaxoSmithKline | Phase 3 |
| Completed | Immunogenicity & Safety Study of GSK Biologicals' 208136 Vaccine Formulated With New Measles and Rubella Worki NCT00892775 | GlaxoSmithKline | Phase 2 |
| Unknown | Serological Evaluation of Varicella and Hepatitis A Vaccines Using Injector Delivery NCT00926419 | University of Sao Paulo General Hospital | Phase 2 / Phase 3 |
| Completed | Study to Test the Safety and Immunogenicity of VARIVAX (2007 Process) (Study V210-057) (Completed) NCT00822237 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Safety of a Second Dose of Biken's Varicella Vaccine NCT00830648 | Sanofi Pasteur, a Sanofi Company | Phase 4 |
| Completed | Immunogenicity & Safety Study of GSK Biologicals' Combined Measles-mumps-rubella-varicella Vaccine 208136 NCT00751348 | GlaxoSmithKline | Phase 3 |
| Terminated | A Study of ProQuad™ in Healthy Children in Korea (V221-023) NCT00839917 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Comparative Study of Immunogenicity and Safety of a 2-dose Regimen of ProQuad® Manufactured With rHA (V221-038 NCT00566527 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Immunogenicity and Safety of GlaxoSmithKline Biologicals' MMRV Vaccine vs. ProQuad® in Children 12-14 Months o NCT00578175 | GlaxoSmithKline | Phase 2 |
| Completed | Study of Two Formulations of GSK Biologicals' Varicella Vaccine NCT00568334 | GlaxoSmithKline | Phase 2 |
| Completed | Special Drug Use Investigation for VALTREX (Valaciclovir) (Pediatrics Chickenpox) NCT01390857 | GlaxoSmithKline | — |
| Completed | Safety Study of ProQuad® rHA in Infants (V221-037) NCT00560755 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Evaluation of Vaccination Reminder/Recall Systems for Adolescent Patients NCT00715234 | University of Colorado, Denver | N/A |
| Completed | Re-examination Study For Varivax (V210-059 AM2) NCT01062061 | Merck Sharp & Dohme LLC | — |
| Unknown | Immunity Against Varicella in Pediatric Orthotopic Liver Transplantation Recipients NCT00492739 | University Hospital, Geneva | Phase 2 / Phase 3 |
| Completed | Study of the Safety of Menactra® Vaccine When Administered With Other Pediatric Vaccines to Healthy Toddlers NCT00483574 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Immunogenicity and Safety Study of Proquad® and Infanrix® Hexa When Administered Concomitantly (V221-035) NCT00432042 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers NCT00422292 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | ProQuad® Intramuscular vs Subcutaneous NCT00402831 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | A Study of 2 Doses of Menactra®, a Meningococcal Conjugate Vaccine in Healthy Toddlers NCT00384397 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Immunogenicity, Safety of Measles-mumps-rubella-varicella Vaccine (MeMuRu-OKA) Compared to Priorix™ Given With NCT00352898 | GlaxoSmithKline | Phase 2 |
| Completed | Immunogenicity, Safety of Measles-mumps-rubella-varicella Vaccine (MeMuRu-OKA) Compared to Priorix™ Given With NCT00353288 | GlaxoSmithKline | Phase 2 |
| Completed | V221 Concomitant Use Study With Pneumococcal Conjugate Vaccine (V221-019) NCT00109343 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Immunogenicity/Safety of Measles-Mumps-Rubella-Varicella Vaccine (MeMuRu-OKA): Using Two Different Administrat NCT00351923 | GlaxoSmithKline | Phase 3 |
| Approved For Marketing | Safety and Efficacy of Varicella Zoster Immune Globulin (Human) VariZIG in Patients at Risk of Varicella Infec NCT00338442 | Cangene Corporation | — |
| Completed | Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases NCT00127010 | GlaxoSmithKline | Phase 3 |
| Terminated | Immune Responses to Two Dose Varivax +/- MMR-II NCT00258726 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 / Phase 2 |
| Completed | Evaluate Vaccine Against Chickenpox and a Combined Vaccine Against 4 Viral Childhood Diseases: Measles, Mumps, NCT00226499 | GlaxoSmithKline | Phase 3 |
| Completed | Safety,Tolerability and Immunogenicity of Vaccination With VARIVAX in Healthy Indian Children (V210-056) NCT00496327 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Detection and Characterisation of Varicella Zoster Virus From Dermal Lesions of Chickenpox-infected Patients NCT00127608 | GlaxoSmithKline | Phase 3 |
| Completed | Immunogenicity and Safety of Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases NCT00126997 | GlaxoSmithKline | Phase 4 |
| Completed | Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases NCT00127023 | GlaxoSmithKline | Phase 3 |
| Completed | Evaluation Of Valaciclovir In Patients With Chickenpox NCT00169416 | GlaxoSmithKline | Phase 3 |
| Completed | Immunogenicity and Safety of Concomitant Administration of MMR™ rHA and VARIVAX® by Intramuscular Versus Subcu NCT00432523 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Safety Study of a Refrigerator-stable Formulation of VARIVAX® NCT00432731 | Merck Sharp & Dohme LLC | Phase 4 |
| Completed | Long-term Follow-up on Immunogenicity & Safety of Measles-Mumps-Rubella-Varicella (MMRV) Combined Vaccine NCT00406211 | GlaxoSmithKline | Phase 3 |
| Terminated | Responses of Premature Infants to Measles-Mumps-Rubella (MMR) and Varicella Vaccines NCT00138255 | National Institute of Allergy and Infectious Diseases (NIAID) | — |
| Completed | Immunogenicity and Safety of GSK Biologicals' Live Attenuated Varicella Vaccine (VARILRIXTM). NCT00792623 | GlaxoSmithKline | Phase 2 |
| Completed | Study to Evaluate Frozen Versus Refrigerated MMRV (Combined Measles, Mumps, Rubella, and Varicella) Investigat NCT00092430 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Safety, Tolerability, and Immunogenicity of an Investigational Vaccine With Recombinant Human Albumin (rHA) in NCT00092404 | Merck Sharp & Dohme LLC | Phase 2 |
| Completed | A Study of ProQuad in Healthy 4 to 6 Year Old Children (V221-014) NCT00985166 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Frozen ProQuad Administered Concomitantly Versus Nonconcomitantly With Other Pediatric Vaccines NCT00984295 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Safety, Tolerability, and Immunogenicity of 3 Frozen ProQuad Consistency Lots in Healthy Children (V221-012)(C NCT00985153 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | ProQuad Dose Selection Study (V221-011)(COMPLETED) NCT00986232 | Merck Sharp & Dohme LLC | Phase 2 |
| Completed | A Study of An Approved Vaccine at Mumps Expiry Potency in Healthy Children 12 to 18 Months of Age (V205C-007)( NCT00092391 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | ProQuad™ Versus M-M-R II™ and VARIVAX™ in Healthy Children (V221-009)(COMPLETED) NCT00975507 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | A Study to Evaluate Long-term Impact of VARIVAX Among Children and Adolescents (V210-036)(COMPLETED) NCT01077804 | Merck Sharp & Dohme LLC | — |
| Completed | Tai Chi Chih and Varicella Zoster Immunity NCT00029484 | National Center for Complementary and Integrative Health (NCCIH) | Phase 2 |